Should doctors be 'selling' drugs for the pharmaceutical industry?

Feature: Key opinion leaders -- independent experts or drug representatives in disguise?
Are senior doctors who help drug companies sell their drugs independent experts or just drug representatives in disguise, asks Ray Moynihan from the University of Newcastle in Australia, in this week's BMJ.

Moynihan exposes the reality behind the practice with some candid revelations from industry insiders.

Pharmaceutical companies regularly sponsor leading specialists with "generous fees to peddle influence" and promote drugs to the profession and the public, writes Moynihan.

Drug companies will pay influential doctors up to $400 an hour to act as key opinion leaders, and some doctors earn more than $25 000 a year in advisory fees.

Kimberly Elliot, a former award-winning drug company sales representative interviewed* by Moynihan, reveals that drug companies desperately need key opinion leaders in order for doctors to believe what they are saying and prescribe their products, because drug representatives are often not believed. Essentially, she says, key opinion leaders are just salespeople.

So how independent are these doctors who have long term financial arrangements with drug companies?

According to Richard Tiner, medical director at the Association of the British Pharmaceutical Industry, although "the work might help to promote a particular medicine" it should be considered payment for work done, and not a bribe. The best antidote to concerns about independence would be more transparency—all company payments to speakers should be routinely disclosed at medical meetings, he adds.

But David Blumenthal, from Harvard University, believes that payments to key opinion leaders are not in the public interest or in the interests of the patients served by these doctors, and calls for a major cutback in industry influence over the medical profession and its education.

In an accompanying head to head, Charlie Buckwell, Chief Executive of the Complete Medical Group and Professor Giovannii Fava, from the University of Bologna, debate whether drug companies' use of medical experts is essential for medical advancement or whether it risks scientific integrity.

Source: BMJ-British Medical Journal

Related stories:

NC State first university in nation to offer canine bone marrow transplants
Dogs suffering from lymphoma will be able to receive the same type of medical treatment as their human counterparts, as North Carolina State University becomes the first university in the nation to offer canine bone marrow transplants in a clinical setting.
Ondansetron reduces vomiting, hospital admissions in children with gastroenteritis
University of North Carolina at Chapel Hill researchers have demonstrated that a drug called ondansetron helps reduce vomiting, the need for intravenous fluids and hospital admissions in children with acute gastroenteritis.
Value of direct-to-consumer drug advertising oversold, study finds
Direct-to-consumer advertising may not be giving big pharma such a big bang for their buck after all. Despite the billions spent on bringing drug marketing campaigns straight into patients' living rooms, such strategies have a modest effect at best—and in some cases, no effect at all.
Doctors say Vytorin-cancer link can't be ruled out
(AP) -- Results from three studies of the cholesterol-lowering drug Vytorin are not enough to prove or rule out a possible link to a higher risk of cancer, so the drug should be used with great caution until more is known, editors of a leading medical journal urged Tuesday.
Watch out for drug names that look, sound alike
(AP) -- Take the generic drug clonidine for high blood pressure? Double-check that you didn't leave the drugstore with Klonopin for seizures, or the gout medicine colchicine.
Suicide risks studied in drugs for physical ills
(AP) -- Cody Miller was a high school football player who was allergic to ragweed. Douglas Briggs was a doctor coping with pain from an old back injury. Both are now dead, hanging victims driven to suicide, their families believe, when drugs prescribed to relieve physical symptoms upset their mental and emotional balance. Federal drug regulators are investigating to see if the families could be right.
Study: Bypass better than stents in long term
(AP) -- For heart patients with clogged arteries, the choice between bypass surgery or an angioplasty may come down to one question: How many procedures would you like to have? In research presented Monday at the European Society of Cardiology meeting in Munich, experts concluded that while bypass surgery and angioplasty offer comparable results, patients who have angioplasties are twice as likely to require another procedure within a year.
Risk of repeat attacks in heart patients causes concern for doctors
An international study, led by the University of Edinburgh, raises concerns that some patients may not be receiving the optimum medical treatment and follow-up care because doctors are misjudging the risk of a further heart attack.

News discussion:

Medicine & Health news